EUVIMEDEUVIMED entdecken
Crossref

Treatment of Recurrent Epidermolysis Bullosa Acquisita With Tofacitinib

Birao Fan, Mingyue Wang

JAMA Dermatology · 2023

DOI: 10.1001/jamadermatol.2022.6250 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Dermatology, 2023. Verfasst von Birao Fan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Epidermolysis Bullosa Acquisita, Epidermolysis Bullosa. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This case report describes a patient with recurrent epidermolysis bullosa acquisita who was treated with tofacitinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epidermolysis Bullosa AcquisitaEpidermolysis BullosaHumansSkinPiperidinesPyrimidines

Substanzen

tofacitinibPiperidinesPyrimidines

Autor:innen und Institutionen

  • Department of Dermatology, Peking University First Hospital, Beijing, China.
  • National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
  • Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.

Zitieren

APA

Fan, B., & Wang, M. (2023). Treatment of Recurrent Epidermolysis Bullosa Acquisita With Tofacitinib. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2022.6250

Vancouver

Fan B, Wang M. Treatment of Recurrent Epidermolysis Bullosa Acquisita With Tofacitinib. JAMA Dermatology. 2023. doi:10.1001/jamadermatol.2022.6250

BibTeX
@article{Fan2023,
  author = {Fan, Birao and Wang, Mingyue},
  title = {Treatment of Recurrent Epidermolysis Bullosa Acquisita With Tofacitinib},
  journal = {JAMA Dermatology},
  year = {2023},
  doi = {10.1001/jamadermatol.2022.6250}
}
Kostenlos starten →